Goffe Ben, Cather Jennifer Clay
Department of Dermatology, University of Washington, 515 Minor Avenue, Suite 200, Seattle, WA 98104, USA.
J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S105-11. doi: 10.1016/mjd.2003.554.
Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
依那西普是肿瘤坏死因子-α（TNF-α）的竞争性抑制剂，目前已获美国食品药品监督管理局（FDA）批准用于治疗银屑病关节炎和类风湿关节炎。本文将对依那西普的分子结构、作用机制以及涉及银屑病患者的临床试验结果进行综述。
